In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly EL-468, a phenylenediamine, possesses the delayed-toxicity necessary for a bait toxicant to control colonies of the red imported fire ant, Solenopsis invicta Buren. In laboratory tests it ...

Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly ...

Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug addiction, making it the first major ...

Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.' ...